SCHEMBL10285854

SCHEMBL10285854

CCCCOc1ccc2c(C)cc(=O)[nH]c2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.65
PPARA Q07869 1/20 0.61
GLA P06280 2/20 0.58
GAA P10253 2/20 0.58
ALDH1A1 P00352 3/20 0.51
TP53 P04637 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HPGD P15428 1/20 0.51
GPR84 Q9NQS5 1/20 0.49
TNKS2 Q9H2K2 4/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
GPR17 Q13304 1/20 0.47
DRD3 P35462 1/20 0.46
CYP2D6 P10635 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
XDH P47989 1/20 0.46
TSHR P16473 1/20 0.45
CTSV O60911 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1039281 0.90 KDM4E (0.63) KDM4EPPARAGLAGAAALDH1A1
SCHEMBL1038244 0.88 KDM4E (0.61) KDM4EPPARAGLAGAAALDH1A1
SCHEMBL30634405 0.79 KDM4E (1.00) KDM4EGLAGAAALDH1A1TP53
SCHEMBL394584 0.79 KDM4E (1.00) KDM4EGLAGAAALDH1A1TP53
SCHEMBL2795363 0.78 CTSV (0.65) KDM4EPPARAGLAGAAALDH1A1
SCHEMBL10285857 0.78 DRD2 (0.53) KDM4EALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL12247567 0.78 HTR1B (0.50) KDM4ETP53CYP1A2CYP2C19GPR17
SCHEMBL17439462 0.78 KDM4E (0.57) KDM4EPPARAGLAGAAALDH1A1
SCHEMBL11068508 0.78 LMNA (0.54) KDM4EPPARAGLAGAAALDH1A1
SCHEMBL10572539 0.77 KDM4E (0.58) KDM4EPPARAGLAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524738-B2 Quinolinones and quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2013-09-03 US disclosed
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-08-23 US disclosed
EP-2468743-A1 Nitrogen-containing bicyclic compounds useful as antibacterial agents Toyama Chemical Co., Ltd. (JP) 2012-06-27 EP disclosed
EP-1900732-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2008-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION NQO2, ASNS, NDUFS1 KDM4E 2555/4885PPARA 3024/4885GLA 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.